Browsing Other ICR Research by title
Now showing items 1-20 of 404
-
Access to clinical trials for adolescents with soft tissue sarcomas: Enrollment in European pediatric Soft tissue sarcoma Study Group (EpSSG) protocols.
(2017-06)BACKGROUND: Adolescents with cancer are enrolled in clinical trials at far lower rates than children. This report compares the number of adolescents (15-19-year-olds) and children (0-14-year-olds) enrolled in the protocols ... -
Acute myeloid leukemia xenograft success prediction: Saving time.
(2018-03)Xenograft assay allows functional analysis of leukemia-initiating cells of acute myeloid leukemia primary samples. However, 40% of samples derived from patients with better outcomes fail to engraft in immunodeficient mouse ... -
Adherence to Guidelines for Adult (Non-GIST) Soft Tissue Sarcoma in the Netherlands: A Plea for Dedicated Sarcoma Centers.
(2017-10)INTRODUCTION: Optimal management of soft tissue sarcoma (STS) remains a challenge. A nationwide survey assessed the quality of STS care in the Netherlands, thereby aiming to identify potentialities for improvement through ... -
Adjuvant chemotherapy may improve disease-free survival in patients with mrEMVI-positive rectal cancer following chemoradiation.
(2016-09-27)MRI-detected extramural venous invasion (mrEMVI) is a poor prognostic factor in rectal cancer. Pre-operative chemoradiotherapy (CRT) can cause regression in the severity of EMVI and subsequently improve survival whereas ... -
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
BACKGROUND: Combination therapy with the BRAF inhibitor dabrafenib plus the MEK inhibitor trametinib improved survival in patients with advanced melanoma with BRAF V600 mutations. We sought to determine whether adjuvant ... -
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.
BACKGROUND: Nivolumab and ipilimumab are immune checkpoint inhibitors that have been approved for the treatment of advanced melanoma. In the United States, ipilimumab has also been approved as adjuvant therapy for melanoma ... -
Advanced roles in cancer nursing
(2017-05-25) -
Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW.
(2018-04)BACKGROUND AND AIM: REGARD and RAINBOW were global, phase 3, randomized, double-blind trials of second-line ramucirumab for metastatic gastric or gastroesophageal junction adenocarcinoma. Exploratory subgroup analyses were ... -
Aggressive haematological malignancies
(2017-10)
